Literature DB >> 22004899

β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.

David R Murray1, Srinivas Mummidi, Anthony J Valente, Tadashi Yoshida, Naveen K Somanna, Patrice Delafontaine, Charles A Dinarello, Bysani Chandrasekar.   

Abstract

Both the sympathetic nervous system and the proinflammatory cytokine interleukin-18 (IL-18) play key roles in the pathophysiology of the hypertrophied failing heart. IL-18 binding protein (IL-18BP), a natural inhibitor of IL-18, counters its biological effects. β-AR stimulation induces IL-18 expression, but whether it also regulates IL-18BP is not known. Here we demonstrate that the β-AR agonist isoproterenol (ISO) increases steady state IL-18BP mRNA and protein levels in adult mouse cardiomyocytes in a β(2)-AR-dependent manner. We cloned mouse Il18bp 5'cis-regulatory region, and identified putative CREB and C/EBPβ transcription factor-binding sites. Forced expression of mutant CREB or C/EBPβ knockdown markedly attenuated ISO-induced Il18bp transcription and deletion or mutation of CREB and C/EBP motifs in the Il18bp promoter reduced ISO-induced promoter-reporter gene activity. ISO induced CREB and C/EBPβ activation in cardiomyocytes via PI3K/Akt and ERK1/2. Importantly, ISO-induced hypertrophy in vitro was dependent on IL-18 induction as it was blunted by IL-18 neutralizing antibodies and forced expression of IL-18BP. Moreover, ISO-induced hypertrophy was markedly attenuated in IL-18 null and IL-18BP transgenic mice. These data support the novel concept that β-AR activation, in addition to inducing cardiomyocyte hypertrophy via IL-18, concomitantly induces a countering effect by stimulating IL-18BP expression, and that ISO-induced cardiomyocyte hypertrophy may result from a net effect of IL-18 and IL-18BP induction.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004899      PMCID: PMC3246026          DOI: 10.1016/j.yjmcc.2011.09.022

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  42 in total

Review 1.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2002-11-29       Impact factor: 17.367

2.  A cAMP response element in the beta 2-adrenergic receptor gene confers transcriptional autoregulation by cAMP.

Authors:  S Collins; J Altschmied; O Herbsman; M G Caron; P L Mellon; R J Lefkowitz
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

3.  A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation.

Authors:  Jeanne Mialet-Perez; Stuart A Green; William E Miller; Stephen B Liggett
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

4.  Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction.

Authors:  B Stein; P C Cogswell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

5.  Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6.

Authors:  C Kunsch; R K Lang; C A Rosen; M F Shannon
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

6.  Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8.

Authors:  T Matsusaka; K Fujikawa; Y Nishio; N Mukaida; K Matsushima; T Kishimoto; S Akira
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

7.  Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice.

Authors:  R L Smeets; F A J van de Loo; O J Arntz; M B Bennink; L A B Joosten; W B van den Berg
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

8.  Generation and characterization of mice transgenic for human IL-18-binding protein isoform a.

Authors:  Giamila Fantuzzi; Nirmal K Banda; Carla Guthridge; Andrea Vondracek; Soo-Hyun Kim; Britta Siegmund; Tania Azam; Joseph A Sennello; Charles A Dinarello; William P Arend
Journal:  J Leukoc Biol       Date:  2003-08-11       Impact factor: 4.962

9.  Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB.

Authors:  Bysani Chandrasekar; Federica M Marelli-Berg; Masahide Tone; Sailaja Bysani; Sumanth D Prabhu; David R Murray
Journal:  Biochem Biophys Res Commun       Date:  2004-06-25       Impact factor: 3.575

10.  Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins.

Authors:  Stephen J Perry; George S Baillie; Trudy A Kohout; Ian McPhee; Maria M Magiera; Kok Long Ang; William E Miller; Alison J McLean; Marco Conti; Miles D Houslay; Robert J Lefkowitz
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

View more
  14 in total

1.  β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt.

Authors:  Laurel A Grisanti; Jennifer A Talarico; Rhonda L Carter; Justine E Yu; Ashley A Repas; Scott W Radcliffe; Hoang-Ai Tang; Catherine A Makarewich; Steven R Houser; Douglas G Tilley
Journal:  J Mol Cell Cardiol       Date:  2014-02-22       Impact factor: 5.000

Review 2.  Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

Authors:  Cameron S Brand; Janet K Lighthouse; Michael A Trembley
Journal:  J Mol Cell Cardiol       Date:  2019-04-28       Impact factor: 5.000

3.  PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction.

Authors:  Walter E Knight; Si Chen; Yishuai Zhang; Masayoshi Oikawa; Meiping Wu; Qian Zhou; Clint L Miller; Yujun Cai; Deanne M Mickelsen; Christine Moravec; Eric M Small; Junichi Abe; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-20       Impact factor: 11.205

4.  Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.

Authors:  Polina Sysa-Shah; Carlo G Tocchetti; Manveen Gupta; Peter P Rainer; Xiaoxu Shen; Byung-Hak Kang; Frances Belmonte; Jian Li; Yi Xu; Xin Guo; Djahida Bedja; Wei Dong Gao; Nazareno Paolocci; Rutwik Rath; Douglas B Sawyer; Sathyamangla V Naga Prasad; Kathleen Gabrielson
Journal:  Cardiovasc Res       Date:  2015-12-21       Impact factor: 10.787

Review 5.  Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.

Authors:  Qin Fu; Qingtong Wang; Yang K Xiang
Journal:  Trends Endocrinol Metab       Date:  2017-02-28       Impact factor: 12.015

Review 6.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

7.  Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death.

Authors:  Tadashi Yoshida; Ingeborg Friehs; Srinivas Mummidi; Pedro J del Nido; Solange Addulnour-Nakhoul; Patrice Delafontaine; Anthony J Valente; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2014-08-07       Impact factor: 5.000

Review 8.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

9.  Induction of M2 regulatory macrophages through the β2-adrenergic receptor with protection during endotoxemia and acute lung injury.

Authors:  Jamison J Grailer; Mikel D Haggadone; J Vidya Sarma; Firas S Zetoune; Peter A Ward
Journal:  J Innate Immun       Date:  2014-03-14       Impact factor: 7.349

10.  CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy.

Authors:  Anthony J Valente; Robert A Clark; Jalahalli M Siddesha; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2012-04-26       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.